| Dr Gladys Telang, MD | |
|
593 Eddy St, Apc 10, Providence, RI 02903-4923 | |
| (401) 444-7959 | |
| (401) 444-7144 |
| Full Name | Dr Gladys Telang |
|---|---|
| Gender | Female |
| Speciality | Pathology |
| Experience | 37 Years |
| Location | 593 Eddy St, Providence, Rhode Island |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1063466621 | NPI | - | NPPES |
| 710000523 | Medicaid | RI | |
| 9025522 | Medicaid | RI | |
| 709004108 | Other | RI | GROUP MEDICARE |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207ZD0900X | Pathology - Dermatopathology | MD10812 (Rhode Island) | Secondary |
| 207N00000X | Dermatology | MD10812 (Rhode Island) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Kent County Memorial Hospital | Warwick, RI | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Affinity Physicians Llc. | 0244413391 | 619 |
| Brown Dermatology Inc | 3870872773 | 27 |
News Archive
Patients with acute coronary syndromes (ACS) who are at high risk for bleeding have significantly lower rates of target lesion revascularisation and fewer adverse events after undergoing percutaneous coronary intervention (PCI) with a polymer-free biolimus-A (BA9) drug-coated stent than with those receiving a bare metal stent (BMS) in results from a sub-study of the LEADERS FREE trial reported for the first time in a late-breaker session at EuroPCR 2016.
New research published in Cell Reports identifies a potential treatment target for blinding diseases such as retinitis pigmentosa and advanced dry age-related macular degeneration.
The multiple sclerosis (MS) therapy alemtuzumab can trigger severe, unpredictable side effects.
According to the Centers for Disease Control and Prevention (CDC), hip replacements are among the most common surgical procedures in the United States; and with osteoarthritis and obesity on the rise, demand for the procedure is expected to grow.
› Verified 5 days ago
| Entity Name | Newport Hospital |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1063632180 PECOS PAC ID: 0042111437 Enrollment ID: O20040422000696 |
News Archive
Patients with acute coronary syndromes (ACS) who are at high risk for bleeding have significantly lower rates of target lesion revascularisation and fewer adverse events after undergoing percutaneous coronary intervention (PCI) with a polymer-free biolimus-A (BA9) drug-coated stent than with those receiving a bare metal stent (BMS) in results from a sub-study of the LEADERS FREE trial reported for the first time in a late-breaker session at EuroPCR 2016.
New research published in Cell Reports identifies a potential treatment target for blinding diseases such as retinitis pigmentosa and advanced dry age-related macular degeneration.
The multiple sclerosis (MS) therapy alemtuzumab can trigger severe, unpredictable side effects.
According to the Centers for Disease Control and Prevention (CDC), hip replacements are among the most common surgical procedures in the United States; and with osteoarthritis and obesity on the rise, demand for the procedure is expected to grow.
› Verified 5 days ago
| Entity Name | Affinity Physicians Llc. |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1184944662 PECOS PAC ID: 0244413391 Enrollment ID: O20110326000053 |
News Archive
Patients with acute coronary syndromes (ACS) who are at high risk for bleeding have significantly lower rates of target lesion revascularisation and fewer adverse events after undergoing percutaneous coronary intervention (PCI) with a polymer-free biolimus-A (BA9) drug-coated stent than with those receiving a bare metal stent (BMS) in results from a sub-study of the LEADERS FREE trial reported for the first time in a late-breaker session at EuroPCR 2016.
New research published in Cell Reports identifies a potential treatment target for blinding diseases such as retinitis pigmentosa and advanced dry age-related macular degeneration.
The multiple sclerosis (MS) therapy alemtuzumab can trigger severe, unpredictable side effects.
According to the Centers for Disease Control and Prevention (CDC), hip replacements are among the most common surgical procedures in the United States; and with osteoarthritis and obesity on the rise, demand for the procedure is expected to grow.
› Verified 5 days ago
| Entity Name | Rhode Island Hospital |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1154537520 PECOS PAC ID: 8921900044 Enrollment ID: O20141017000105 |
News Archive
Patients with acute coronary syndromes (ACS) who are at high risk for bleeding have significantly lower rates of target lesion revascularisation and fewer adverse events after undergoing percutaneous coronary intervention (PCI) with a polymer-free biolimus-A (BA9) drug-coated stent than with those receiving a bare metal stent (BMS) in results from a sub-study of the LEADERS FREE trial reported for the first time in a late-breaker session at EuroPCR 2016.
New research published in Cell Reports identifies a potential treatment target for blinding diseases such as retinitis pigmentosa and advanced dry age-related macular degeneration.
The multiple sclerosis (MS) therapy alemtuzumab can trigger severe, unpredictable side effects.
According to the Centers for Disease Control and Prevention (CDC), hip replacements are among the most common surgical procedures in the United States; and with osteoarthritis and obesity on the rise, demand for the procedure is expected to grow.
› Verified 5 days ago
| Entity Name | Brown Dermatology Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1730538026 PECOS PAC ID: 3870872773 Enrollment ID: O20161117000508 |
News Archive
Patients with acute coronary syndromes (ACS) who are at high risk for bleeding have significantly lower rates of target lesion revascularisation and fewer adverse events after undergoing percutaneous coronary intervention (PCI) with a polymer-free biolimus-A (BA9) drug-coated stent than with those receiving a bare metal stent (BMS) in results from a sub-study of the LEADERS FREE trial reported for the first time in a late-breaker session at EuroPCR 2016.
New research published in Cell Reports identifies a potential treatment target for blinding diseases such as retinitis pigmentosa and advanced dry age-related macular degeneration.
The multiple sclerosis (MS) therapy alemtuzumab can trigger severe, unpredictable side effects.
According to the Centers for Disease Control and Prevention (CDC), hip replacements are among the most common surgical procedures in the United States; and with osteoarthritis and obesity on the rise, demand for the procedure is expected to grow.
› Verified 5 days ago
| Entity Name | The Miriam Hospital |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1598978744 PECOS PAC ID: 6901796408 Enrollment ID: O20170303000645 |
News Archive
Patients with acute coronary syndromes (ACS) who are at high risk for bleeding have significantly lower rates of target lesion revascularisation and fewer adverse events after undergoing percutaneous coronary intervention (PCI) with a polymer-free biolimus-A (BA9) drug-coated stent than with those receiving a bare metal stent (BMS) in results from a sub-study of the LEADERS FREE trial reported for the first time in a late-breaker session at EuroPCR 2016.
New research published in Cell Reports identifies a potential treatment target for blinding diseases such as retinitis pigmentosa and advanced dry age-related macular degeneration.
The multiple sclerosis (MS) therapy alemtuzumab can trigger severe, unpredictable side effects.
According to the Centers for Disease Control and Prevention (CDC), hip replacements are among the most common surgical procedures in the United States; and with osteoarthritis and obesity on the rise, demand for the procedure is expected to grow.
› Verified 5 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Gladys Telang, MD 593 Eddy St, Apc 10, Providence, RI 02903-4923 Ph: (401) 444-7959 | Dr Gladys Telang, MD 593 Eddy St, Apc 10, Providence, RI 02903-4923 Ph: (401) 444-7959 |
News Archive
Patients with acute coronary syndromes (ACS) who are at high risk for bleeding have significantly lower rates of target lesion revascularisation and fewer adverse events after undergoing percutaneous coronary intervention (PCI) with a polymer-free biolimus-A (BA9) drug-coated stent than with those receiving a bare metal stent (BMS) in results from a sub-study of the LEADERS FREE trial reported for the first time in a late-breaker session at EuroPCR 2016.
New research published in Cell Reports identifies a potential treatment target for blinding diseases such as retinitis pigmentosa and advanced dry age-related macular degeneration.
The multiple sclerosis (MS) therapy alemtuzumab can trigger severe, unpredictable side effects.
According to the Centers for Disease Control and Prevention (CDC), hip replacements are among the most common surgical procedures in the United States; and with osteoarthritis and obesity on the rise, demand for the procedure is expected to grow.
› Verified 5 days ago
Pooya Jahanshahi, M.D. Dermatology Medicare: Accepting Medicare Assignments Practice Location: 593 Eddy St, Providence, RI 02903 Phone: 401-444-7139 | |
Antonio P. Cruz, MD Dermatology Medicare: May Accept Medicare Assignments Practice Location: 1287 N Main St, Providence, RI 02904 Phone: 401-272-2724 Fax: 401-272-2784 | |
Dr. Scott Hammerman, M.D. Dermatology Medicare: Accepting Medicare Assignments Practice Location: 50 Maude St Fl 1, Department Of Dermatology And Skin Surgery, Providence, RI 02908 Phone: 401-456-2315 Fax: 410-456-6449 | |
Dr. Raymond Henry Welch, M.D. Dermatology Medicare: Not Enrolled in Medicare Practice Location: 845 N Main St, Suite 3, Providence, RI 02904 Phone: 401-521-7300 Fax: 401-521-7307 | |
Helena Marie Kuhn, MD Dermatology Medicare: Accepting Medicare Assignments Practice Location: 593 Eddy St, Apc 10, Providence, RI 02903 Phone: 401-444-7959 Fax: 401-444-7144 | |
Dr. Shoshana Landow, M.D. Dermatology Medicare: Not Enrolled in Medicare Practice Location: 593 Eddy Street,, Apc-10, Providence, RI 02903 Phone: 401-444-7959 Fax: 401-444-7144 | |
Laura Della Torre, M.D. Dermatology Medicare: Accepting Medicare Assignments Practice Location: 1539 Atwood Ave Ste 301, Providence, RI 02919 Phone: 401-490-4515 Fax: 401-490-4516 |